Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program.

ABSTRACT:

Aims/hypothesis

An increased risk of fracture with canagliflozin vs placebo was reported from the CANagliflozin cardioVascular Assessment Study (CANVAS) Program, with heterogeneity of findings identified between the two trials that comprise the CANVAS Program, CANVAS and CANVAS-R. The objective of these analyses was to identify reasons for the possibly different effects on fracture observed between CANVAS and CANVAS-R.

Methods

This study was an analysis of two highly similar trials, CANVAS and CANVAS-R, conducted in 10,142 individuals with type 2 diabetes and history or high risk of cardiovascular disease who received canagliflozin (pooled 100/300 mg once daily) or placebo. Outcomes assessed in this analysis were effects on adjudicated fractures overall and by type, location

SUBMITTER: Zhou Z 

PROVIDER: S-EPMC6731200 | biostudies-literature | 2019 Oct

REPOSITORIES: biostudies-literature